Journal article icon

Journal article

Nicotine receptor partial agonists for smoking cessation.

Abstract:

BACKGROUND: Nicotine receptor partial agonists may help smokers to quit by a combination of maintaining moderate levels of dopamine to counteract withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction (acting as an antagonist). Varenicline was developed as a nicotine receptor partial agonist from cytisine, a drug widely used in central and eastern Europe for smoking cessation. The first trial reports of varenicline were released in 2006, and further trials are underway....

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Primary Care Health Sciences, PHC-Cochrane
Journal:
The Cochrane database of systematic reviews
Volume:
12
Issue:
1
Pages:
CD006103
Publication date:
2007
DOI:
EISSN:
1469-493X
ISSN:
1469-493X
URN:
uuid:1f398155-644c-4cd4-b963-990b4fc010a6
Source identifiers:
24092
Local pid:
pubs:24092

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP